Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Xiaoer Chaigui antipyretic oral liquid is a Traditional Chinese Medicine (TCM) formulation specifically developed for pediatric use to treat fever associated with acute upper respiratory tract infections. Developed by the First Affiliated Hospital of Tianjin University of Chinese Medicine, the formula is based on classical TCM principles, combining elements of the Xiao Chai Hu and Gui Zhi decoctions. Its primary active ingredients include *Radix Bupleuri*, *Ramulus Guizhi*, *Radix Scutellariae*, and *Radix Puerariae*. The preparation works by inducing diaphoresis to expel pathogens from the body's exterior, clearing internal heat, and relieving symptoms such as fever, headache, nasal congestion, and sore throat. It is widely utilized in China as a standard treatment for wind-heat type common colds and influenza in children.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Xiaoer Chaigui antipyretic oral liquid.